Cost-Effectiveness and Economic Impact of Bladder Cancer Management: An Updated Review of the Literature

Daniel D. Joyce, Vidit Sharma, Stephen B. Williams

Research output: Contribution to journalReview articlepeer-review

6 Scopus citations


Bladder cancer remains one of the costliest malignancies to manage. We provide a narrative review of literature assessing the economic burden and cost-effectiveness of bladder cancer treatment and surveillance. This is an update to a previous review and focuses on data published within the past 10 years. We queried PubMed and MEDLINE for all bladder cancer cost-related literature between 2013 and 2023. After initial screening, 117 abstracts were identified, 50 of which were selected for inclusion in our review. Management of disease recurrence and treatment complications contributes significantly to the high cost of care. High-value interventions are therefore treatments that improve recurrence-free and overall survival at minimal additional toxicity. De-escalation of surveillance and diagnostic interventions may help to reduce costs in this space without compromising oncologic control. The persistently rising cost of novel cancer drugs undermines their value when only modest gains in efficacy are observed. Multiple cost-effectiveness analyses have been published and are useful for contextualizing the cost, efficacy, and impact on quality of life that interventions have in this population. Further cost-effectiveness work is needed to better characterize the impact that treatment costs have on patients’ financial well-being and quality of life.

Original languageEnglish (US)
Pages (from-to)751-769
Number of pages19
Issue number7
StatePublished - Jul 2023

ASJC Scopus subject areas

  • Pharmacology
  • Health Policy
  • Public Health, Environmental and Occupational Health


Dive into the research topics of 'Cost-Effectiveness and Economic Impact of Bladder Cancer Management: An Updated Review of the Literature'. Together they form a unique fingerprint.

Cite this